平均心脏剂量不足以替代左前降支剂量预测肺癌放疗后主要不良心脏事件风险
该回顾性研究纳入701例接受放疗的局部晚期非小细胞肺癌患者,分析平均心脏剂量(MHD)与左前降支(LAD)V15Gy之间的不一致性及其与主要不良心脏事件(MACE)风险的关系。结果显示MHD仅能解释LAD V15Gy 54.5%的方差,23.1%患者存在剂量分类不一致,且孤立性低LAD V15Gy显著降低MACE风险,提示全心脏指标预测心脏事件的有效性需重新评估。
要点
- MHD仅能预测LAD V15Gy 54.5%的方差,二者分类不一致见于23.1%患者。
- MHD高/LAD低者2年MACE累积发生率为4.2%,显著低于MHD低/LAD高者的13.0%。
- 校正混杂因素后,MHD高/LAD低和MHD低/LAD低均与MACE风险显著降低相关。
核心结论
- MHD不足以可靠预测LAD V15Gy,当二者剂量暴露不一致时,孤立性低LAD V15Gy显著降低局部晚期NSCLC放疗后MACE风险。
- 提示应重新评估全心脏指标预测心脏事件的有效性。
研究设计与样本
- 回顾性分析701例接受放疗的局部晚期非小细胞肺癌患者。
- 计算MHD与LAD V15Gy的决定系数,按MHD≥10 Gy vs <10 Gy和LAD V15Gy≥10% vs <10%分为四组。
- 采用Fine和Gray回归分析MACE累积发生率。
主要发现
- MHD可预测LAD V15Gy的方差比例仅为54.5%(R²=0.545)。
- 23.1%(n=162)患者存在MHD与LAD V15Gy分类不一致。
- 2年MACE估计值:MHD高/LAD低4.2%,MHD高/LAD高7.6%,MHD低/LAD低1.8%,MHD低/LAD高13.0%。
关键数值与推荐
- MHD高定义为≥10 Gy,低定义为<10 Gy;LAD V15Gy高定义为≥10%,低定义为<10%。
- MACE包括不稳定型心绞痛、心力衰竭、心肌梗死、冠状动脉血运重建和心源性死亡。
临床怎么用
- 放疗计划评估中不应仅依赖MHD,应单独关注LAD受照剂量如V15Gy。
- 对于MHD高但LAD V15Gy低的患者,心脏事件风险可能较低,可避免过度担心。
- 对于MHD低但LAD V15Gy高的患者,需警惕较高的MACE风险并加强监测。
局限性
- 回顾性分析设计可能存在选择偏倚和未测量混杂因素。
- 样本来自单中心或特定人群,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mean heart dose (MHD) over 10 Gy and left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15Gy) greater than 10% can significantly increase the risk of major adverse cardiac events (MACE) in patients with non-small cell lung cancer (NSCLC). We sought to characterize the discordance between MHD and LAD dose and the association of this classification on the risk of MACE after radiation therapy. METHODS AND MATERIALS: The coefficient of determination for MHD and LAD V15Gy was calculated in this retrospective analysis of 701 patients with locally advanced NSCLC treated with radiation therapy. Four groups were defined on the basis of high or low MHD (≥10 Gy vs <10 Gy) and LAD V15Gy (≥10% vs <10%). MACE (unstable angina, heart failure, myocardial infarction, coronary revascularization, and cardiac death) cumulative incidence was estimated, and Fine and Gray regressions were performed. RESULTS: The proportion of variance in LAD V15Gy predictable from MHD was only 54.5% (R2 = 0.545). There was discordance (where MHD was high [≥10 Gy] and LAD low [V15Gy < 10%], or vice versa) in 23.1% of patients (n = 162). Two-year MACE estimates were 4.2% (MHDhigh/LADlow), 7.6% (MHDhigh/LADhigh), 1.8% (MHDlow/LADlow), and 13.0% (MHDlow/LADhigh). Adjusting for pre-existing coronary heart disease and other prognostic factors, MHDhigh/LADlow (subdistribution hazard ratio [SHR], 0.34; 95% CI, 0.13-0.93; P = .036) and MHDlow/LADlow (SHR, 0.24; 95% CI, 0.10-0.53; P < .001) were associated with a significantly reduced risk of MACE. CONCLUSIONS: MHD is insufficient to predict LAD V15Gy with confidence. When MHD and LAD V15Gy dose exposure is discordant, isolated low LAD V15Gy significantly reduces the risk of MACE in patients with locally advanced NSCLC after radiation therapy, suggesting that the validity of whole heart metrics for optimally predicting cardiac events should be reassessed.
引用
- Atkins KM, Bitterman DS, Chaunzwa TL, et al. Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33713743. doi:10.1016/j.ijrobp.2021.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。